TNF and psoriasis vulgaris: Among the investigated biologics, secukinumab was the most used, followed by ustekinumab and TNF inhibitors (17.8%)—mainly adalimumab—a ranking that roughly reflects the prescription patterns for moderate-severe plaque psoriasis in Italy.